>欧洲急性呼吸窘迫综合征 (ARDS) 市场，按原因（2019 年冠状病毒病 (COVID-19)、败血症、吸入有害物质、严重肺炎等）、类型（诊断和治疗）、给药途径（口服、肠外和其他）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（直接招标、医院药房、零售药房、网上药房等）、国家（德国、英国、意大利、法国、西班牙、瑞士、俄罗斯、土耳其、匈牙利、立陶宛、奥地利、爱尔兰、挪威、波兰、荷兰和欧洲其他地区）、行业趋势和预测到 2029 年。
欧洲急性呼吸窘迫综合征 (ARDS) 市场分析和规模
急性呼吸窘迫综合征 (ARDS) 是一种危及生命的肺部损伤，会导致液体渗入肺部。大多数患有 ARDS 的人已经因创伤或 COVID-19 等疾病住院。这种综合征通常发生在肺部微小的弹性气囊（称为肺泡）中积聚液体时。这种液体积聚会导致更少的氧气进入血液。这使器官无法获得足够的氧气来维持正常功能。患有其他疾病的人在诱发损伤或感染后的几小时到几天内会患上 ARDS。死亡风险随着年龄的增长而增加，并且根据疾病的严重程度，患者很难从该综合征中幸存下来。严重的疾病或伤害会导致肺膜囊受损，从而导致 ARDS。上述疾病最常见的潜在原因包括败血症、吸入有害物质、严重肺炎、头部、胸部或其他重大伤害、2019 年冠状病毒病 (COVID-19) 等。
急性肺损伤的患病率和发病率不断上升、ARDS 的各种风险因素以及 COVID-19 患者群体的加速增长，这些因素推动了急性呼吸窘迫综合征 (ARDS) 市场的发展。预计推动欧洲急性呼吸窘迫综合征 (ARDS) 市场增长的其他因素包括空气污染和生活方式相关疾病的发生率不断上升，以及事故率和创伤性 ARDS 的发生率不断上升。
然而，治疗并发症以及设备和治疗的高成本等因素阻碍了欧洲急性呼吸窘迫综合征 (ARDS) 市场的增长。另一方面，老年人口的增长、医疗支出的增加以及市场参与者的战略举措为欧洲急性呼吸窘迫综合征 (ARDS) 市场的增长提供了机会。严格的审批规定和 ICU 护士面临的多重挑战是欧洲急性呼吸窘迫综合征 (ARDS) 市场面临的关键市场挑战。
Data Bridge Market Research analyses that the Europe Acute Respiratory Distress Syndrome (ARDS) market is expected to reach a value of USD 5,291.89 million by 2029, at a CAGR of 9.5% during the forecast period. "Coronavirus Disease 2019 (COVID-19)" accounts for the most prominent technology segment due to its wide infectious and contagious nature, progressively developing respiratory illnesses such as pneumonia and acute respiratory distress syndrome. The acute respiratory distress syndrome (ARDS) market report also comprehensively covers pricing analysis, patent analysis, and technological advancements.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Segments Covered |
By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Type (Diagnosis, and Treatment), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others). |
|
Countries Covered |
Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Netherlands, and the Rest of Europe. |
|
Market Players Covered |
Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Gilead Sciences, Inc., Fresenius SE & Co. KGaA, Armstrong Medical, Smiths Medical, ResMed, Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., Terumo Medical Corporation, Getinge AB., and EUROSETS, among others. |
Market Definition
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. Most people who get ARDS are already hospitalized for trauma or illness like COVID-19. The syndrome usually occurs when fluids build up in the lungs' tiny, elastic air sacs called alveoli. This fluid build-up causes less oxygen to reach the bloodstream. This deprives the organs of getting enough oxygen for their normal function. People with other illnesses develop ARDS within a few hours to days after the precipitating injury or infection. The risk of death increases with age, and depending on the severity of the illness, patients surviving the syndrome becomes hard.
Severe illness or injury which causes damage to the membrane sacs of the lungs leads to ARDS. The most common underlying causes for the said diseases include sepsis, inhalation of harmful substances, severe pneumonia, head, chest, another major injury, coronavirus disease 2019 (COVID-19), and others.
Acute Respiratory Distress Syndrome (ARDS) Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Increasing prevalence and incidence of acute lung injury
The increasing alcohol consumption, irrespective of age, leads to syndrome-like ARDS. Other risk factors like dyspnoea, hypertension, diabetes, and more lead to ARDS development. Thereby, this wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are anticipated to boost the growth of the market.
- Wide range of risk factors for ARDS
The increasing alcohol consumption, irrespective of age, leads to syndrome-like ARDS. Other risk factors like dyspnoea, hypertension, diabetes, and more lead to ARDS development. Thereby, this wide range of risk factors associated with acute respiratory distress syndrome increases the possibility of developing the clinical condition, simultaneously raising the cases of the disease. These affirmative risk factors are anticipated to boost the growth of the market.
- Acceleration in the patient pool of COVID-19 with ARDS
The rising number of COVID-19 cases also increases the chance of acute respiratory distress syndrome among people, which is expected to act as a driver for the growth of the acute respiratory distress syndrome market.
- Rising rate of air pollution and lifestyle-related diseases
The World Health Organization, air pollution is one of the greatest environmental risks to health by increasing the burden of diseases like heart diseases and lung and respiratory infections at both acute and chronic levels. Hence, the rising air pollution rate in developed and developing countries increases the chances of people getting syndromes like acute respiratory distress syndrome. Thus, the factor is expected to drive the growth of the market.
- Increasing accident rates and trauma causing ARDS
The inhalation of smoke releases materials like fibrin, neutrophils, mucus, and epithelial cell debris that occlude the airway lumen, causing changes in ventilation. This condition leads to hypoxemia which is a primary significant reason for ARDS. They also reported that increased mortality rates in burn patients were due to ARDS. Thereby, the rising accidents and trauma injuries in the lungs are expected to drive the growth of the market
Restraint
- Complications associated with treatments
There are treatments for ARDS helping people survive, but the complications associated with treatments and post-treatment are still a burden for patients. Most potential and lasting effects include breathing problems, depression, problems with memory and thinking, tiredness and muscle weakness, and more.
These complications associated with and post-treatment of acute respiratory distress syndrome are expected to hamper the market growth during our forecast period.
- High cost of device and treatments
The high cost of ventilation treatment per day is not affordable if the therapy has to proceed for many days. Hence patients prefer taking ventilators for home care. However, the price of ventilators is yet quite expensive. Therefore, the high cost of treatment and ventilators is very challenging for people to afford any reliable remedy for the long term until the patient completely recovers. This is anticipated to hamper the growth of the market.
- Lack of skilled workforce
There were shortages of nurses even before the pandemic began in the U.S. as the region has a high number of population with respiratory disorders. Therefore, the lack of appropriately skilled and trained nurses in the ICU will be a more remarkable restraint expected to hamper the growth of the acute respiratory distress syndrome (ARDS) market.
Post COVID-19 Impact on Acute Respiratory Distress Syndrome (ARDS) Market
The pandemic of COVID-19, the rising prevalence of acute respiratory distress syndrome and lung failure, which is commonly seen in COVID-19 patients, has increased the demand for ventilators, respiratory equipment, peak flow meters, and the treatment products like antiviral and steroidal drugs in hospitals and this is accelerating the market growth. Therefore, during this pandemic, the demand for ventilators, humidifiers, respiratory inhalers, and certain drugs for respiratory healing problems is very high. According to the situation report of 6th January 2022 by WHO stated, 288.86 million cumulative cases of coronavirus have been reported globally, and 5.43 million patients are dead due to the coronavirus. America is leading in cumulative cases with a record of 104.69 million and 2.4 million death rates, followed by Europe with 103 million cumulative cases and 1.67 million cumulative deaths. The outbreak of COVID-19 is having a huge impact on the healthcare and supply chain of various medical products, including respiratory products and ventilators.
COVID-19 is a serious concern in the new era, where ARDS (Acute Respiratory Distress Syndrome) and lung failure are most commonly seen in COVID-19 patients. As reported by healthcare professionals, pneumonia caused by the SARS-CoV-2 virus usually presents with fever, dyspnea, and acute respiratory symptoms, which can lead to ARDS, a life-threatening form of respiratory failure. Therefore this sudden surge of COVID-19 patients and associated ARDS illness, the demand for the market is higher in this forecasted period.
It is anticipated that the COVID-19 pandemic outbreak will have a positive impact on the growth of the market due to the enormous requirement and application of such products for respiratory disorders, COVID-19 infection, ARDS, and more. The company’s manufacturing and supply process resumed with steady ease of supply restrictions made by the government recently worldwide.
此外，欧洲各国政府的医疗保健组织也支持这些产品的供应，因为这些产品在这一关键的健康危机时期具有很高的优先性。考虑到病毒的传染性和未来经济的改善，许多政府机构和重要的市场参与者与患者和制药行业密切相关，以确保产品和药品的安全包装。
近期发展
- 2020 年 1 月，ResMed 推出 AirTouch N20 泡沫 CPAP 面罩，这是该公司有史以来最柔软的鼻罩 - ResMed 的首款鼻记忆泡沫垫增强了患者的舒适度和便利性，并且按适当的时间表更换时无需清洁。AirTouch N20 是 ResMed 易于使用、方便且更舒适的面罩系列中的最新产品。这有助于该公司扩大其产品组合。
- 2021 年 2 月，辉瑞公司 CentreOne 宣布了新的 API 和中间体活动。该活动专注于为药品开发商和制造商提供全面的复杂 API 化合物和中间体。此次活动的推出帮助该公司在美国市场获得了提升。
欧洲急性呼吸窘迫综合征 (ARDS) 市场范围
急性呼吸窘迫综合征 (ARDS) 市场根据病因、类型、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
按原因分类
- 2019 冠状病毒病 (Covid-19)
- 脓毒症
- 吸入有害物质
- 严重肺炎
- 其他的
根据病因，欧洲急性呼吸窘迫综合征 (ARDS) 市场细分为 2019 年冠状病毒病 (COVID-19)、败血症、吸入有害物质、严重肺炎等。
按类型
- 诊断
- 治疗
根据类型，欧洲急性呼吸窘迫综合征 (ARDS) 市场分为诊断和治疗。
按 给药途径
- 口服
- 家长
- 其他的
根据给药途径，欧洲急性呼吸窘迫综合征 (ARDS) 市场分为口服、肠外和其他。
按最终用户
- 医院
- 专科诊所
- 家庭医疗保健
- 其他的
根据最终用户，欧洲急性呼吸窘迫综合征 (ARDS) 市场分为医院、专科诊所、家庭医疗保健和其他。
按分销渠道
- 直接招标
- 医院药房
- 零售药店
- 网上药店
- 其他的
根据分销渠道，欧洲急性呼吸窘迫综合征 (ARDS) 市场细分为直接招标、医院药房、零售药房、网上药房和其他。
急性呼吸窘迫综合征 (ARDS) 市场区域分析/见解
对急性呼吸窘迫综合征 (ARDS) 市场进行了分析，并按原因、类型、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势，如上所述。
急性呼吸窘迫综合征 (ARDS) 市场报告涵盖的国家包括德国、英国、意大利、法国、西班牙、瑞士、俄罗斯、土耳其、匈牙利、立陶宛、奥地利、爱尔兰、挪威、波兰、荷兰和欧洲其他地区。
德国在欧洲急性呼吸窘迫综合征 (ARDS) 市场占据主导地位。由于该地区研究活动不断增加以及生物技术和制药业的兴起，德国占据了市场主导地位。这将推动欧洲地区对急性呼吸窘迫综合征 (ARDS) 产品的需求。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。
竞争格局和急性呼吸窘迫综合征 (ARDS) 市场份额分析
急性呼吸窘迫综合征 (ARDS) 市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对急性呼吸窘迫综合征 (ARDS) 市场的关注有关。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CAUSE LIFELINE CURVE IN EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES
4.3 PIPELINE ANALYSIS
4.4 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS
4.4.1 REGULATION IN EUROPE:
4.5 INSURANCE REIMBURSEMENT
4.5.1 CERN HEALTH INSURANCE SCHEME
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS
5.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS
5.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES
5.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS
5.2 RESTRAINTS
5.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS
5.2.2 HIGH COST OF DEVICE AND TREATMENTS
5.2.3 LACK OF SKILLED WORKFORCE
5.3 OPPORTUNITIES
5.3.1 GROWING GERIATRIC POPULATION
5.3.2 RISING HEALTHCARE EXPENDITURE
5.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
5.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME
5.4 CHALLENGES
5.4.1 STRINGENT RULES & REGULATIONS
5.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES
6 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE
6.1 OVERVIEW
6.2 CORONAVIRUS DISEASE 2019 (COVID-19)
6.3 SEPSIS
6.4 INHALATION OF HARMFUL SUBSTANCES
6.5 SEVERE PNEUMONIA
6.6 OTHERS
7 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE
7.1 OVERVIEW
7.2 DIAGNOSIS
7.2.1 IMAGING TESTS
7.2.1.1 CHEST X-RAY
7.2.1.2 CT SCAN
7.2.1.3 ULTRASOUND
7.2.1.4 OTHERS
7.2.2 BLOOD TEST
7.2.3 RESPIRATORY RATE
7.2.4 SPO2 TEST
7.2.5 OTHERS
7.3 TREATMENT
7.3.1 MECHANICAL VENTILATION
7.3.1.1 HIGH-FLOW NASAL O2
7.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE
7.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE
7.3.1.4 PRONE POSITIVE VENTILATION
7.3.1.5 OTHERS
7.3.2 CORTICOSTEROIDS
7.3.2.1 METHYLPREDNISOLONE
7.3.2.2 DEXAMETHASONE
7.3.2.3 OTHERS
7.3.3 ANTIVIRAL MEDICATION
7.3.3.1 REMDESIVIR
7.3.3.2 COMBINATION DRUGS
7.3.3.3 OTHERS
7.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
7.3.5 TOCILIZUMAB
7.3.6 OTHERS
8 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 PARENTERAL
8.2.1 INTRAVENOUS
8.2.2 INTRAMUSCULAR
8.3 ORAL
8.4 OTHERS
9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 HOME HEALTHCARE
9.5 OTHERS
10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT TENDER
10.3 HOSPITAL PHARMACY
10.4 RETAIL PHARMACY
10.5 ONLINE PHARMACY
11 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 TURKEY
11.1.7 HUNGARY
11.1.8 NETHERLANDS
11.1.9 SWITZERLAND
11.1.10 AUSTRIA
11.1.11 LITHUANIA
11.1.12 POLAND
11.1.13 RUSSIA
11.1.14 IRELAND
11.1.15 NORWAY
11.1.16 REST OF EUROPE
12 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GILEAD SCIENCES INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUS ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 TERUMO CORPORATION
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUS ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 GETINGE AB
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUS ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 LIVANOVA PLC
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENTS
14.5 MEDTRONIC
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENTS
14.6 ARMSTRONG MEDICAL
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 DRÄGERWERK AG & CO. KGAA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 EUROSETS
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 F. HOFFMANN-LA ROCHE LTD
14.9.1 COMPANY SNAPSHOT
14.9.2 RECENT ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENTS
14.1 FISHER & PAYKEL HEALTHCARE LIMITED
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 FRESENIUS SE & CO. KGAA
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUS ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 HAMILTON MEDICAL
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 PFIZER INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUS ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 RESMED
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 SMITHS MEDICAL
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUS ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: PIPELINE ANALYSIS
TABLE 2 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 3 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 EUROPE IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 12 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 13 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 14 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 EUROPE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 25 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 26 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 27 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 28 GERMANY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 GERMANY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 GERMANY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 GERMANY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 GERMANY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 GERMANY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 34 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 35 GERMANY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 36 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 37 GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 38 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 39 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 FRANCE DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 FRANCE IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 FRANCE TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 FRANCE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 FRANCE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 FRANCE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 47 FRANCE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 48 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 51 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 U.K. DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 U.K. IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 U.K. TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 U.K. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 U.K. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 U.K. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 59 U.K. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 60 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 61 U.K. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 62 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 63 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 ITALY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 ITALY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 ITALY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 ITALY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 ITALY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 ITALY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 71 ITALY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 72 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 73 ITALY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 74 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 75 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 SPAIN DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 SPAIN IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 SPAIN TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 SPAIN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 SPAIN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 SPAIN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 83 SPAIN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 84 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 85 SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 86 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 87 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 TURKEY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 TURKEY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 TURKEY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 TURKEY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 TURKEY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 TURKEY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 95 TURKEY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 96 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 97 TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 99 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 HUNGARY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 HUNGARY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 HUNGARY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 HUNGARY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 HUNGARY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 HUNGARY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 107 HUNGARY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 108 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 HUNGARY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 111 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 NETHERLANDS DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 NETHERLANDS IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 NETHERLANDS TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 NETHERLANDS ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 NETHERLANDS CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 NETHERLANDS MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 119 NETHERLANDS PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 120 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 123 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 SWITZERLAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 SWITZERLAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 SWITZERLAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 SWITZERLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 SWITZERLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 SWITZERLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 131 SWITZERLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 132 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 133 SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 134 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 135 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 AUSTRIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 AUSTRIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 AUSTRIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 AUSTRIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 AUSTRIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 AUSTRIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 143 AUSTRIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 144 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 145 AUSTRIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 146 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 147 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 LITHUANIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 LITHUANIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 LITHUANIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 LITHUANIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 LITHUANIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 LITHUANIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 154 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 155 LITHUANIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 156 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 LITHUANIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 158 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 159 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 POLAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 POLAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 162 POLAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 POLAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 POLAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 POLAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 167 POLAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 168 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 169 POLAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 170 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 171 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 RUSSIA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 RUSSIA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 RUSSIA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 RUSSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 RUSSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 RUSSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 179 RUSSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 180 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 181 RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 182 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 183 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 184 IRELAND DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 185 IRELAND IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 IRELAND TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 187 IRELAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 IRELAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 189 IRELAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 191 IRELAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 192 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 193 IRELAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 194 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 195 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 NORWAY DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 197 NORWAY IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 NORWAY TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 199 NORWAY ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 NORWAY CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 201 NORWAY MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 202 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 203 NORWAY PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 204 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 205 NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 206 REST OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 2 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF ACUTE LUNG INJURIES IS EXPECTED TO DRIVE THE EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
FIGURE 14 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2021
FIGURE 15 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2020-2029 (USD MILLION)
FIGURE 16 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2022-2029)
FIGURE 17 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 18 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2021
FIGURE 19 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 20 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 21 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 23 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 24 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 25 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2021
FIGURE 27 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 28 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 29 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DISTRIBUTION CHANNEL, 2021
FIGURE 31 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 32 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 33 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SNAPSHOT (2021)
FIGURE 35 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021)
FIGURE 36 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 37 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 38 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE (2022-2029)
FIGURE 39 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
